We invested in Genialis because we believe their technology can assist us in identifying patients with higher chances of responding to treatment and thus improving the likelihood of achieving clinical endpoints and maximizing the programs ROI for Debiopharm and other Pharmaceutical developers. Genialis can also help us in delivering better outcomes for more patients by prioritizing additional therapeutic opportunities based on potentially responsive patient populations and increasing the speed to successful trial conclusion getting the right treatments to patients faster.